howtogoto BioNTech SE (NASDAQ:BNTX) has been able to achieve several key milestones regarding its pipeline recently. Most notably, it and its partner MedLink Therapeutics [MedLink] had the lifting of the partial clinical hold by the FDA for the antibody drug conjugate [ADC] being developed for the treatment of patients with different types of solid tumors. This candidate is known as BNT326/YL202, which is being advanced in a phase 1 study. With the removal of this partial clinical hold, this allows the  ...